Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. (NASDAQ: BIIB) generates frequent news across neurology, rare diseases and immunology, reflecting its role as a biotechnology company focused on serious neurological and genetic conditions. News coverage for BIIB often centers on clinical trial results, regulatory milestones, scientific publications and strategic collaborations that shape the company’s therapeutic portfolio.
Investors and healthcare observers following Biogen news can expect updates on marketed therapies such as SPINRAZA (nusinersen) for 5q spinal muscular atrophy, QALSODY (tofersen) for SOD1-ALS, and LEQEMBI (lecanemab-irmb) for early Alzheimer’s disease, co-developed with Eisai. Recent announcements have included European Commission approval of a high-dose SPINRAZA regimen, long-term QALSODY data published in JAMA Neurology, and multiple LEQEMBI data presentations at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, including subcutaneous administration and long-term treatment analyses.
Biogen news also highlights its collaborations and pipeline. Examples include joint updates with Stoke Therapeutics on zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome, and a research collaboration with Dayra Therapeutics to discover oral macrocyclic peptides for immunological conditions. In addition, the company regularly issues press releases on scientific conference presentations, regulatory submissions, and its broader ALS and Alzheimer’s research programs.
This BIIB news page aggregates such developments in one place, helping readers track Biogen’s clinical progress, regulatory interactions and research directions over time. For investors, clinicians and researchers, it offers a focused view of how Biogen’s scientific and business activities evolve across its key therapeutic areas.
Biogen Foundation, along with Life Science Cares, has sponsored a $170,000 initiative to support Food For Free's Just Eats Grocery Box program in Greater Boston. This program aims to alleviate food insecurity for 3,000 families, distributing 3,000 grocery boxes weekly. Biogen contributed $100,000, while Life Science Cares provided $50,000. The initiative responds to the growing hunger crisis exacerbated by COVID-19, where one in five children in Eastern Massachusetts now faces food insecurity. The program will utilize local resources to deliver nutritious food to underserved communities.
Biogen (NASDAQ: BIIB) has announced the expiration results of its cash offer to purchase outstanding 5.200% Senior Notes due 2045, totaling $1.75 billion. The Cash Offer expired on February 10, 2021, while the Settlement Date is expected on February 16, 2021. As of the expiration, $8.907 million in Notes were tendered, with an additional $2.864 million expected through guaranteed delivery procedures. The total cash payment for accepted Notes is anticipated at approximately $16 million. The Cash Offer was made solely to Eligible Holders, as defined in the Offer to Purchase.
On February 11, 2021, Biogen announced the results of its private offer to exchange outstanding 5.200% Senior Notes due 2045 for new 3.250% Senior Notes due 2051 and cash. The exchange offer expired on February 10, 2021, with approximately $621 million of the old notes tendered. Biogen expects to issue roughly $721 million in new notes and pay around $156 million in cash at the settlement date, anticipated on February 16, 2021. The exchange will not provide cash proceeds to Biogen, and holders of the old notes will cease to earn interest post-settlement.
Biogen has awarded Golden Tickets to Bolden Therapeutics and Seranova Bio, granting them access to state-of-the-art lab facilities at LabCentral for one year. This initiative highlights Biogen's commitment to innovation in the biotech sector, offering mentorship and shared infrastructure to support promising startups. Bolden Therapeutics aims to develop therapies targeting a novel signaling pathway for CNS diseases, while Seranova Bio focuses on a rapid profiling platform for identifying therapeutic targets. The initiative enhances Biogen's engagement with the local scientific community.
Biogen announced its Cash Offer for $1.75 billion in 5.200% Senior Notes due 2045, set to expire at 5:00 p.m. New York City time today. The Tender Consideration for each $1,000 in principal of Notes is $1,357.12, based on a reference yield of 1.937% and a fixed spread of 115 basis points. The Cash Offer condition includes an Aggregate Maximum Cash Offer Condition of $50 million. Biogen is also offering an Exchange Offer for Ineligible Holders to swap Notes for new senior notes. Settlement for the Cash Offer is expected on February 16, 2021.
Biogen has announced the pricing terms for its private offer to exchange $1.75 billion of its 5.200% Senior Notes due 2045 for new 3.250% Senior Notes due 2051. The Total Exchange Consideration is set at $1,357.12 for each $1,000 of Old Notes. The Exchange Offer will expire today at 5:00 p.m. ET, with the Settlement Date expected by February 16, 2021. Additionally, a cash tender offer for the Old Notes is being made to Ineligible Holders. The offering is set to meet various conditions outlined in the Offering Memorandum.
Biogen (Nasdaq: BIIB) has initiated a cash offer to purchase its outstanding 5.200% Senior Notes due 2045, totaling $1.75 billion. The Cash Offer is subject to a maximum tender consideration of $50 million and will expire on February 10, 2021. Eligible Holders can also participate in a separate exchange offer. The Tender Consideration will be determined based on prevailing market conditions at the time of pricing. This action reflects Biogen's strategy to manage its debt portfolio effectively.
Biogen has announced a private Exchange Offer to swap $1.75 billion of its 5.200% Senior Notes due 2045 for new notes and cash. This offer is available only to "Eligible Holders" who meet specific qualifications. The Exchange Offer will expire on February 10, 2021, and cash payments will be included in the Total Exchange Consideration. Concurrently, Biogen is offering a cash tender to Ineligible Holders. Conditions apply, including a minimum issue amount of $300 million for New Notes. The complete terms are outlined in the Offering Memorandum.
Biogen has received FDA approval for the intramuscular (IM) administration of PLEGRIDY (peginterferon beta-1a) to treat relapsing multiple sclerosis (MS), which is expected to reduce injection site reactions significantly. This follows European Commission authorization in December 2020. PLEGRIDY is already known for its efficacy in reducing relapses and delaying disability progression. The approval was based on studies showing that IM administration resulted in fewer injection site reactions compared to the subcutaneous method (14.4% vs. 32.1%). This adds to Biogen's extensive MS treatment options in over 60 countries.
The FDA has extended the review period for Biogen's aducanumab, a treatment for Alzheimer's, by three months, setting the new PDUFA action date to June 7, 2021. This extension follows Biogen's submission of additional clinical data considered a Major Amendment. Aducanumab, developed in collaboration with Eisai, aims to alter disease progression and improve daily living activities for Alzheimer’s patients. The drug, licensed from Neurimmune, could become the first effective treatment for Alzheimer’s if approved.